Eli Lilly and rival drugmaker Novo Nordisk are the leading companies in the GLP-1 space, but others are emerging. Among them is Pfizer; in September that company announced it would acquire Metsera, a ...

LONDON (Reuters) -Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the ...

Market observers are closely monitoring potential developments in discussions between Eli Lilly and the Trump administration. Reports indicate the company may be nearing a landmark agreement that ...

Eli Lilly and Novo Nordisk are expected to announce price reductions for their weight-loss drugs as part of the TrumpRx ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.

Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...

The White House is close to announcing a deal with drugmakers Eli Lilly and Novo Nordisk that would cut the price of obesity drugs to $149 per month in some cases and extend coverage to certain ...

Eli Lilly and Novo Nordisk are expected to announce deals with the Trump administration to cut prices of their weight-loss ...

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar ...